← Adaptimmune Therapeutics PLC (ADAPY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Adaptimmune Therapeutics PLC (ADAPY)
Biological Products, (No Diagnostic Substances) · market cap $7M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Adaptimmune Therapeutics PLC (ADAPY) is a UK-founded, Philadelphia-headquartered biopharmaceutical company developing T cell therapies for cancer, with links to Oxford University and the University of Pennsylvania. Its lead and only disclosed pipeline asset is NYESO-1c259 T cells in Phase 2 for ovarian cancer. The company trades at approximately $0.03 per share with a market capitalization of roughly $48M, employs 506 people, and has no upcoming catalysts on the public calendar.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NYESO-1c259 T cells | Phase 2 | Ovarian Cancer |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ADAPY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.